Surgery Papers of the Week

Multimodal therapy – including surgery, systemic chemotherapy, and selective radiotherapy – represents the optimal approach when feasible.

We describe an endoscope‐assisted transoral technique using flexible‐tip endoscopy and tailored laryngoscopic exposure for safe, function‐preserving resection.

Methodology: This study employs a retrospective observational study design, analyzing data from patients who underwent emergency surgical procedures at Yirol Hospital over a 12-month period, covering 1 May 2025 to 1 May 2026 and encompassing a diverse cohort presenting with acute trauma and life-threatening surgical emergencies.

An international online survey was conducted among surgeons, oncologists, radiotherapists, and gastroenterologists to assess current perspectives on NAT in AR-PDAC.

Here, we present a prespecified interim analysis of event-free survival.

Here we develop a thermoresponsive positively charged poly(N-isopropylacrylamide) (PNIPAM)/Ga (PGa ) hydrogel sealant, formed by slug-inspired biomimetic self-assembly.

We conducted a prospective, investigator-initiated, multicenter, randomized, open-label trial in China.

Interpretation should take into account that the observed i

A single-center retrospective observational study was conducted at a tertiary endocrine surgery unit.

To further dissect the impact of B cell subtypes, we generated a comprehensive single-cell RNA sequencing database of intratumoral B cells in 12 tumor types from 152 patients. We found a context-dependent role for B cells, in which they are beneficial in certain cancer types and potentially unfavorable in others, with germinal center and memory B cells enriched in favorable prognosis cohorts and immunoglobulin A-positive plasma cells enriched in unfavorable prognosis cohorts.

In the phase 2 UNICORN trial, we evaluated short-course preoperative botensilimab (BOT; multifunctional Fc-enhanced anti-CTLA-4 monoclonal antibody) alone or in combination with the anti-PD-1 monoclonal antibody balstilimab (BOT + BAL) in 56 patients with resectable, locally advanced CC.

The adjusted mean absolute risk difference in 3-year all-cause mortality for those age 80+ years was 4.3 pp ([95% CI, -3.7 to 12.3]; = .62). This emulated target trial found higher 3-year all-cause mortality after SABR versus surgery in early-stage NSCLC suitable for either modality, supporting that surgical resection should remain the preferred option.

We analyzed adult CMI-coded hospitalizations undergoing endovascular or open revascularization in the 2006-2020 National Inpatient Sample.

The aim of this study is to examine the association and possible impact of GLP-1RA on patients with AAA.

This analysis estimated that the average event-free time during the first 36 mo was 31.7 mo (95% CI 30.3-33.1) with perioperative apalutamide plus ADT versus 20.